• MannKind Corporation recently reported that it has enrolled the first pediatric patient in INHALE-1ST, a clinical study evaluating the safety and efficacy of Afrezza (insulin human) Inhalation Powder initiated soon after type 1 diabetes diagnosis in youth aged 10 and above, used alongside once-daily basal insulin.
• This milestone builds on the FDA’s October 2025 acceptance of a supplemental Biologics License Application for pediatric Afrezza, positioning the inhaled insulin as a potential first needle-free insulin option for children in more than 100 years of insulin therapy, pending regulatory review.
• We’ll now examine how launching INHALE-1ST in newly diagnosed pediatric patients could reshape MannKind’s investment narrative around Afrezza’s growth.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

MannKind Investment Narrative Recap

To own MannKind today, you need to believe Afrezza and the broader Technosphere platform can justify a premium valuation despite revenue concentration and ongoing commercialization hurdles. The INHALE-1ST pediatric initiation study directly reinforces Afrezza’s pediatric thesis, but the near term catalyst remains the May 29, 2026 FDA action on the pediatric sBLA, while key risks still center on Afrezza’s uptake, payer access, and the company’s reliance on a narrow product set.

Among recent announcements, the January 26, 2026 FDA-approved update to Afrezza’s adult prescribing information looks especially relevant, because clearer dosing conversion guidance from INHALE-3 and Dose Optimization data could help reduce prescriber hesitation. If adult adoption improves from a simpler label while pediatric use potentially opens up, Afrezza may gain more clinical visibility, though this will still need to contend with MannKind’s high spending and dependence on Afrezza and Tyvaso DPI royalties.

Yet, against this potential upside, the risk that Afrezza remains a niche option, particularly if pediatric uptake stalls or payers resist broader coverage, is something investors should be aware of...

MannKind's narrative projects $437.5 million revenue and $70.4 million earnings by 2028.

Uncover how MannKind's forecasts yield a $9.61 fair value, a 70% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were far more cautious, assuming around US$412.9 million of revenue and US$44.3 million of earnings by 2028, and treating slow Afrezza penetration plus heavy R&D spending as signs that meaningful profitability could remain elusive, which contrasts sharply with more optimistic views and may look different once the pediatric Afrezza data from INHALE-1ST is fully understood.

Explore 3 other fair value estimates on MannKind - why the stock might be worth over 4x more than the current price!

Build Your Own MannKind Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your MannKind research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free MannKind research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MannKind's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.